The need for consistent and optimal performance of cell therapy manufacturing continues to be a critical driver of technological advancement and investments. Implementation of a scalable, integratable workflow can minimize open process steps and reduce manual touchpoints—ultimately reducing manufacturing failures. New innovations in closed, modular, cell therapy specific instrumentation enable the development of robust and reproducible, end-to-end manufacturing processes for clinical and commercial applications. In this symposium, industry leaders will discuss benefits that can be gained from standardizing your manufacturing process and how strategic collaborations can help streamline the transition through the commercialization pipeline

Agenda

8:00am Panel

08:40am Q&A

Speakers:

Øystein Åmellem, Director, Cell Biology, Thermo Fisher Scientific

Xavier De Mollerat Du Jeu, Senior Director of Research and Development, Thermo Fisher Scientific

Justin Skoble, Vice President Technical Operations, Caribou Sciences